111 results about "Breast cancer metastasis" patented technology

The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER− breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER− breast cancer metastasis.

The invention relates to the functional genomic and gene expression detection technology and the analysis technology, and discloses a reagent kit for quantitatively assessing long-term recurrence risks of breast cancer. Particularly, a type of genes capable of being used for breast cancer metastasis and prognostic molecular classification is screened within a human functional genome expression profile range, the detection technology is created, and the reagent kit is prepared and applied to breast cancer metastasis and prognostic assessment for a patient. The reagent kit for quantitatively assessing long-term recurrence risks of breast cancer comprises 21 pairs of primers, 21 specific taqman fluorescent probes, 10XRT-PCR (reverse transcription-polymerase chain reaction) buffer solution, 2.5mM of dNTP (diethyl-nitrophenyl thiophosphate) mixed liquor, reverse transcriptase, DNA (deoxyribose nucleic acid) polymerase, 10XPCR buffer solution and RNA (ribonucleic acid) enzyme inhibitor. The reverse transcription PCR technology is combined with the taqman fluorescent quantitative PCR technology, reverse transcription primers, real-time PCR primers and the taqman fluorescent probes are self-designed and optimized, reverse transcription PCR reagent and taqman fluorescent quantitative PCR reagent are integrated to prepare the detection reagent kit, operation is simple and fast, detection results are more stable, and detection cost is lower.

The present invention relates to a method for the prognosis of bone metastasis in HER2+ breast cancer, which comprises determining if the MAF gene is amplified in a primary tumor sample. Likewise, the present invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the MAF gene expression level, amplification or translocation. The present invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The present invention also relates to a c-Maf inhibitor as therapeutic agent for use in the treatment of HER2+ breast cancer metastasis. The present invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the present invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.

The invention discloses three gene groups for transferring and typing prognostic numerator to breast cancer, a gene chip, an unsupervised clustering map from a gene expression profile and a method for transferring and typing prognostic numerator to breast cancer patients. The invention is characterized in that: the gene chip is point-sampled and prepared by specific cDNA or oligonucleotide of the gene groups with an lattice form on the surface of the supports, and is used for transferring and typing prognostic numerator to breast cancer; the cDNA or amplified products of primary cancer tissue specimens based on breast cancer patients are fluorescence-marked and then crossbred with the gene chip for transferring and typing prognostic numerator to breast cancer, and then the gene expression profile is obtained, and the unsupervised clustering map for transferring and typing prognostic numerator to patients comes from the gene expression profile; the method makes use of the gene chip and the gene expression profile for transferring and typing prognostic numerator to breast cancer.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.

Methods for diagnosis and treatment of cancer using ID4 are disclosed. Specifically, epigenetic inactivation of ID4 in colorectal carcinomas and breast correlates with poor differentiation and unfavorable prognosis. Further, aberrant hypermethylation of ID4 gene promoter region increases risk of metastasis in colorectal and breast cancer.

The invention relates to the technical field of medicines, and relates to adriamycin-indocyanine green bionic nanoparticles coated with platelet and neutrophil fusion membranes and an application of the adriamycin-indocyanine green bionic nanoparticles in preparation of medicines for treating tumor metastasis diseases. The bionic nanoparticle coated with the platelet and neutrophil hybrid membranecomprises adriamycin, indocyanine green, a nano carrier material, a platelet membrane and a neutrophil hybrid membrane, which is characterized by comprising the following components in percentage byweight: 8 to 10 percent of doxorubicin, 8 to 10 percent of indocyanine green, 30 to 40 percent of nano carrier material and the balance of platelet and neutrophile granulocyte hybrid membrane. The bionic nanoparticle has the capability of simultaneously capturing and removing circulating tumor cells and tumor-derived exosomes through a high-affinity membrane adhesion receptor, and effectively cutsoff the relationship between the exosomes and immune cells. The primary tumor can be completely ablated, and breast cancer metastasis can be efficiently inhibited in xenograft and in-situ breast tumor models.

Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.

The invention relates to a gene detection kit for prognosing gastric cancer metastasis. The kit comprises a DNA library building kit, wherein the DNA library building kit comprises a high-risk gene probe and a low-risk gene probe; the high-risk gene probe comprises CDH1, CDH2, SNAIL, SLUG, MUC4, MUC6, PRSS3, USP6, MLH1, MSH2, MSH6, PMS2, TGFBR2, MMP2, MMP9, BRCA1, BRCA2, PALB2, ATM, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1 and XRCC1; the low-risk gene probe comprises ATRX, BRIP1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCO, FANCP, MDM2, MDM4, MLH1, NPM1, PP2R1A, PRKDC, RAD50, STAG2, XRCC5 and CRCC6. The invention further discloses a use method of the kit. The use method comprises the following steps: extracting cfDNA in a blood sample; building a library for the cfDNA through the DNA library building kit, and then sequencing the DNA to obtain a gene overall length sequence; carrying out gene mutation analysis on the gene overall length sequence.

The invention discloses a breast cancer metastasis assessment kit. The breast cancer metastasis assessment kit comprises specific fluorescent quantitative PCR detection primer pairs of total 11 target genes including BIRC5, DHCR7, UBE2C, AZGP1, IL6ST, MGP, RBBP8, STC2, CALM2, OAZ1 and RPL37A and preferably further comprises Taqman probes of the 11 target genes. By detecting the expression levels of the 11 target genes and combining pathological information such as the lymph node status and the tumor size of a breast cancer patient, the relapse and far-end metastasis risks of the breast cancer patient in 10 years can be assessed, the patient can adopt corresponding treatment measures, and excessive treatment is avoided. The kit is easy and convenient to operate, easy to interpret and low in requirement on instruments; in addition, due to the fact that a totally-closed mode is adopted in the whole PCR process, the cross contamination possibility is avoided, and then a result is more precise.

The invention discloses an application of TLCD1 to diagnosis, prognosis and treatment of BC (breast cancer) metastasis. High expression of TLCD1 in tissue and cells with BC bone metastasis is discovered, which predicts shorter survival time without bone metastasis, and in-vitro and in-vivo experiments prove that down-regulated expression of the gene TLCD1 can inhibit BC migration and invasion, sothat BC bone metastasis is inhibited; based on the discoveries, a reagent for detecting TLCD1 gene expression level is provided to be used for preparing a kit for detecting whether BC metastasis occurs and/or a prognosis kit for predicting BC metastasis tendency; a TLCD1 inhibitory reagent is applied to preparation of drugs for preventing and/or treating BC metastasis, and a new idea is provided for diagnosis, prognosis and treatment of BC metastasis.

The invention discloses a miRNA marker related to colorectal cancer metastasis in tissues and application thereof, belonging to fields of biological technology and medical technology. The miRNA markerrelated to colorectal cancer metastasis in tissues is any one or more of miR-96, miR-99b, miR-155, let-7a and let-7b. The screened out miRNA marker related to colorectal cancer metastasis in tissueshas much higher specificity and sensitivity than the tumor marker CEA in clinical use at present in detection of colorectal cancer metastasis, thereby greatly improving the diagnosis accuracy.

Methods are provided for treating cancer patients who have elevated expression of FOXC2. In certain aspects, patients having elevated FOXC2 are treated with an anti-cancer therapy in conjunction with a p38 MAPK inhibitor. Methods of identifying cancer patients to be treated with p38 MAPK inhibitors are also provided. Further provided herein are methods for treating and/or preventing breast cancer metastasis by the administration of a p38 MAPK inhibitor. In certain aspects, patients are treated with an anti-cancer therapy in conjunction with a p38 MAPK inhibitor. In addition, methods are provided for the treatment of BCR-ABL positive cancers, such as acute lymphoblastic leukemia, by the administration of a p38 MAPK inhibitor and/or a glucocorticoid inhibitor in combination with a tyrosine kinase inhibitor.

The invention provides an intelligent breast cancer metastasis therapy device, wherein a safety bed is installed on the lower part of protective resistance wires, the protective resistance wires are densely connected around a chest conduction shell, spraying heads are distributed on the chest conduction shell, a traditional Chinese medicine steam box specifically comprises a steam output pipe, a water inlet hole, a water outlet hole, a heat insulation shell, a traditional Chinese medicine screen and a thermal resistance, an atomization core is installed under the traditional Chinese medicine screen, and the atomization core comprises a main body, a mobile core and a stationary core which are be coupled in a dismountable manner; and a physical sign monitoring platform, an electronic medical record platform and a remote diagnosis and treatment platform are installed on the safety bed. The intelligent breast cancer metastasis therapy device provided by the invention moistens human chest cells by the spraying heads using traditional Chinese medical ingredients in ganoderma spores, and transmits weak currents to a human chest by an intelligent electricity control box, so that partial cancer cells can be effectively killed, a patient's physical signs are monitored all the time during a therapy, intelligence level of the whole device is increased, and side effects brought by the therapy are relieved.

The invention discloses a restructuring protein with phenotypic knock-up effect for chemotactic factor acceptor CXCR4 and constructing method, which is characterized by the following: proceeding twice genetic reform for restructuring muton SDF-1/54R of SDF-1 alpha with CXCR4 antagonistic active; constructing the restructuring protein 54R/Tat/KDEL with SDF-1/54R, high effective wearing film carrier Tat(47-57) and endoplasmic reticulum locating fragment KDEL; utilizing high effective wearing film function of Tat(47-57) and endoplasmic reticulum locating function of KDEL; leading CXCR4 specific antagonist SDF-1/54R into breast cancer cell; reaching the goal of phenotype knock up film surface CXCR4; laying necessary work foundation for blocking-up breast cancer transition.

The invention discloses a breast cancer metastasis therapeutic device which can integrate pointed restoration function treatment and surgery chemoradiotherapy and prevent and treat breast cancer metastasis. The breast cancer metastasis therapeutic device is composed of vibration squeezing friction heads, an adjustable switch, a semi-circular fixer and a square fixer, belongs to the advanced therapeutic technology integrally combining laser, ultrasonic waves, microwaves, therapeutic massage and anti-cancer drug injection and performs treatment for diseased region function restoration and cancer cell spreading prevention. According to a breast cancer metastasis emergence and development principle schematic diagram and a breast cancer metastasis therapeutic principle and technique schematic diagram in a manual, human body system level function decreasing and system level structural damage symmetric mutual restriction causes breast cancer metastasis. By adopting the breast cancer metastasis therapeutic device, system level function decreasing part treatment and surgery chemoradiotherapy cancer cell killing system level structural damage resistant treatment are mutually symmetrically and equivalently promoted and are integrally combined to form an etiological treatment mode, and therefore the treatment purpose of controlling and eliminating breast cancer metastasis is achieved.

The present invention provides a method for screening anti-breast cancer metastasis compounds by using a tumor metastasis gene map. The method comprises: randomly selecting at least one gene from 18 genes such as MMP1, FSCN1, PTGS2, EREG, ANGPTL4, VCAM1, CXCR4, CXCL1, RARRES3, ID1, TNC, LY6E, LTBP1, C10orf116, KRTHB1, KYNU, MAN1A1 and NEDD9; and designing probes, and selecting compounds for converting the expression levels of the genes in breast cancer cells after metastasis to the expression levels of the genes in in-situ carcinoma cells or normal cells. According to the present invention, the 20 compounds are selected through the method, and the cytological level and animal level experiment results demonstrate that the compounds or the combinations thereof exhibit the anti-breast cancermetastasis activity to different degrees.

The present invention relates to methods and compositions for determining whether a cancer patient is at increased risk for developing metastatic spread of the cancer and, if the patient is at increased risk, for treating the patient such that the risk of metastasis is reduced. It is based, at least in part, on the discoveries that overexpression of serpin and serpin secretion by cancer cells and L1CAM-mediated vascular cooption promote metastasis of lung and breast cancer to the brain, and that antagonism of serpin or L1CAM reduced metastasis.

The invention provides a pregnane alkaloid derivative with an effect of resisting breast cancer cell metastasis or a pharmaceutically acceptable salt thereof. The structure of the pregnane alkaloid derivative is shown by a general formula I in the specification, wherein R1 and R2 are independently selected from hydrogen, straight-chain or branched alkyl with the carbon atom number of 1-8, naphthenic base, unsaturated alkyl, benzyl and benzene ring substituted benzyl respectively; or R1R2N is piperidyl or pyrrolyl; R3 and R4 are independently selected from hydrogen and hydroxyl respectively; or R3R4 together represents carbonyl oxygen atoms; R5 and R6 are different substituting groups and are independently selected from hydrogen or methyl respectively; and the pharmaceutically acceptable salt is a salt formed with inorganic acid or organic acid, wherein the inorganic acid or organic acid is selected from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methane sulfonic acid, benzene methane sulfonic acid, oxalic acid, tartaric acid, maleic acid, citric acid or ascorbic acid. The invention also provides an application of the pregnane alkaloid derivative in preparation of a medicament for resisting breast cancer metastasis.